Report

QuickView: Leaders in cartilage repair

co.don is a leading producer of autologous cell and tissue transplants for the treatment of cartilage defects: chondrosphere is used for articular cartilage defects and chondrotransplant DISC is used for spinal disc defects. The products are successfully marketed in Germany (revenues of
€4.5m in FY14, double-digit y-o-y growth). Two clinical trials of chondrosphere are underway (a Phase II and Phase III) to obtain EMA authorisation for EU-wide distribution, targeted for 2017.
Underlying
co.don AG

Co.don AG is a Germany-based company that is active in the tissue engineering and regenerative medicine industry. The Company manufactures cell-based biological drugs for the use in orthopedic and neurosurgical applications. Its products are used for the treatment of focal particular cartilage defects, lumbar disc herniation, non-union fractures and dental disorders. Those include co don chondrotransplant, which is used for cartilage treatment, particularly in the knee area; co don chondrosphere, which is a three-dimensional articular cartilage cultivated outside of the body; co don chondrotransplant DISC, for the regeneration of intervertebral discs, and co don osteotransplant DENT, which is an autologous bone cell transplant for dental applications. The Company is active domestically and in other European countries.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch